Vistagen Therapeutics, Inc. (VTGN)
0.3079
+0.01
(+3.32%)
USD |
NASDAQ |
Sep 30, 16:00
0.2952
-0.01
(-4.12%)
After-Hours: 20:00
Vistagen Therapeutics Max Drawdown (5Y) : 99.78% for Aug. 31, 2026
Max Drawdown (5Y) Chart
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| August 31, 2026 | 99.78% |
| July 31, 2026 | 99.78% |
| June 30, 2026 | 99.78% |
| May 31, 2026 | 99.51% |
| April 30, 2026 | 99.51% |
| March 31, 2026 | 99.51% |
| February 28, 2026 | 99.51% |
| January 31, 2026 | 99.48% |
| December 31, 2025 | 99.36% |
| November 30, 2025 | 98.38% |
| October 31, 2025 | 98.38% |
| September 30, 2025 | 98.38% |
| August 31, 2025 | 98.38% |
| July 31, 2025 | 98.38% |
| June 30, 2025 | 98.38% |
| May 31, 2025 | 98.38% |
| April 30, 2025 | 98.38% |
| March 31, 2025 | 98.38% |
| February 28, 2025 | 98.38% |
| January 31, 2025 | 98.38% |
| December 31, 2024 | 98.38% |
| November 30, 2024 | 98.38% |
| October 31, 2024 | 98.38% |
| September 30, 2024 | 98.38% |
| August 31, 2024 | 98.38% |
| Date | Value |
|---|---|
| July 31, 2024 | 98.38% |
| June 30, 2024 | 98.38% |
| May 31, 2024 | 98.38% |
| April 30, 2024 | 98.38% |
| March 31, 2024 | 98.38% |
| February 29, 2024 | 98.38% |
| January 31, 2024 | 98.38% |
| December 31, 2023 | 98.38% |
| November 30, 2023 | 98.38% |
| October 31, 2023 | 98.38% |
| September 30, 2023 | 98.38% |
| August 31, 2023 | 98.38% |
| July 31, 2023 | 98.38% |
| June 30, 2023 | 98.37% |
| May 31, 2023 | 98.21% |
| April 30, 2023 | 98.21% |
| March 31, 2023 | 98.21% |
| February 28, 2023 | 98.21% |
| January 31, 2023 | 98.21% |
| December 31, 2022 | 98.21% |
| November 30, 2022 | 98.21% |
| October 31, 2022 | 98.21% |
| September 30, 2022 | 98.21% |
| August 31, 2022 | 98.21% |
| July 31, 2022 | 98.21% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Max Drawdown (5Y) Benchmarks
| Onconetix, Inc. | -- |
| ACADIA Pharmaceuticals, Inc. | 77.18% |
| Alnylam Pharmaceuticals, Inc. | 58.17% |
| Anika Therapeutics, Inc. | 83.15% |
| Savara, Inc. | 96.98% |
Max Drawdown (5Y) Related Metrics
| Alpha (5Y) | -76.43 |
| Beta (5Y) | 0.3935 |
| Annualized Standard Deviation of Monthly Returns (5Y Lookback) | 156.2% |
| Historical Sharpe Ratio (5Y) | -0.4665 |
| Historical Sortino (5Y) | -1.036 |
| Monthly Value at Risk (VaR) 5% (5Y Lookback) | 56.47% |